Comparative Pharmacology
Head-to-head clinical analysis: BROVANA versus XOPENEX HFA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROVANA versus XOPENEX HFA.
BROVANA vs XOPENEX HFA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BROVANA (arformoterol tartrate) is a long-acting beta2-adrenergic agonist (LABA). It stimulates intracellular adenyl cyclase, increasing cyclic AMP levels, leading to relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.
Selective beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing intracellular cyclic AMP via activation of adenylyl cyclase.
15 mcg (2 mL) by nebulization twice daily, not to exceed 30 mcg/day.
2 inhalations (90 mcg each) every 4-6 hours as needed via oral inhalation. Maximum 12 inhalations per 24 hours.
None Documented
None Documented
Terminal elimination half-life: approximately 26 hours (range 22–30 hours) in healthy adults; prolonged in hepatic impairment (up to 50% increase).
Terminal elimination half-life: 3-4 hours; clinical context: dosing every 4-6 hours for bronchodilation
Primarily renal (60% unchanged drug); remainder via biliary/fecal (approximately 20%) and metabolic transformation.
Renal: 80-100% as unchanged drug and metabolites; fecal: minimal (<5%)
Category C
Category C
Bronchodilator
Bronchodilator